Search

Your search keyword '"Goldberg, Judith D."' showing total 23 results

Search Constraints

Start Over You searched for: Author "Goldberg, Judith D." Remove constraint Author: "Goldberg, Judith D." Journal journal of clinical oncology Remove constraint Journal: journal of clinical oncology
23 results on '"Goldberg, Judith D."'

Search Results

2. Examination of speakership gender disparity at an international oncology conference.

3. Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

4. Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.

5. A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

6. Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.

7. Methylation profiling of locally advanced rectal cancer (LARC): Exploration of potential predictive markers for neoadjuvant chemoradiation (NACR).

9. Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial

13. Concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer: A feasibility trial.

15. Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).

16. Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and local radiotherapy in the treatment of breast cancer chest wall recurrences or skin metastases.

17. Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).

18. RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial.

19. Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study.

20. Loss of nuclear p27KIP1 (p27) expression as a predictor of lymph node spread in T1 breast cancer.

21. Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.

Catalog

Books, media, physical & digital resources